Semax vs Selank: Which Nootropic Peptide to Research?
Semax and Selank are the two most extensively studied cognitive peptides from the Russian research programme. Both are approved in Russia, both are intranasal, and both improve cognitive function — but through entirely different pathways. Semax elevates BDNF and drives neuroplasticity; Selank reduces anxiety through GABAergic and serotonergic modulation.
Semax
ACTH 4–10 analogue
- ✓Elevates BDNF — most studied neurotrophin
- ✓Phase 3 clinical data for stroke recovery
- ✓Mildly stimulatory — focus and clarity
- ✓Intranasal for direct CNS delivery
- ✓Approved in Russia for cognitive conditions
Selank
Tuftsin analogue
- ✓GABA-A modulation without sedation
- ✓No dependency risk — not a benzo
- ✓Phase 2/3 data for generalised anxiety
- ✓Intranasal for rapid CNS delivery
- ✓Calming without cognitive impairment
Side-by-Side Comparison
| Factor | Semax | Selank |
|---|---|---|
| Origin | Synthetic analogue of ACTH 4–10 fragment | Stabilised analogue of endogenous tuftsin |
| Primary Mechanism | BDNF elevation, NGF upregulation, neuroprotection | GABA-A modulation, serotonin transport, dopamine system |
| Primary Effect | Cognitive enhancement, neuroplasticity, focus | Anxiolytic, mood stabilisation, stress resilience |
| Stimulatory/Calming | Mildly stimulatory | Calming without sedation |
| Clinical Data | Phase 3 data for ischaemic stroke; Russian registry approval | Phase 2/3 data for GAD; approved in Russia as anxiolytic |
| BDNF Effect | Direct — elevates BDNF acutely and chronically | Indirect — some BDNF modulation via serotonin pathways |
| Anxiety Reduction | Moderate — secondary via BDNF and neuroprotection | Primary — direct GABAergic and serotonergic anxiolysis |
| Administration | Intranasal (preferred) or SC | Intranasal (preferred) or SC |
| Dependency Risk | None identified | None — not a benzodiazepine mechanism |
| Best Research Focus | Neuroplasticity, stroke recovery, focus, cognitive enhancement | Anxiety disorders, stress, PTSD, mood regulation |
Mechanism Deep Dive
How Semax Works
Semax is a 7-amino-acid peptide derived from the ACTH 4–10 fragment, with modifications (Pro-Gly-Pro appended) that protect it from enzymatic degradation in the nasal mucosa and allow transport into the CNS via the olfactory route.
Its primary mechanism is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the hippocampus and cortex. BDNF is the most studied neurotrophin for learning, memory, and neuronal survival — elevated BDNF drives synaptic plasticity (LTP) and promotes neurogenesis.
Semax also has a neuroprotective profile via VEGF upregulation and anti-inflammatory cytokine modulation. Its Phase 3 clinical trials for ischaemic stroke demonstrated improved recovery outcomes — making it one of the few peptides with hard clinical endpoints in CNS research.
How Selank Works
Selank is a synthetic analogue of tuftsin — an endogenous immunopeptide — with a Pro-Gly-Pro C-terminal extension that protects it from rapid degradation. It acts through multiple neurotransmitter systems simultaneously, which distinguishes it from single-target anxiolytics.
Its primary action is allosteric modulation of GABA-A receptors, producing anxiolytic effects without the receptor downregulation or dependency risk associated with direct agonists like benzodiazepines. It also inhibits serotonin uptake transporters and modulates dopaminergic transmission.
Crucially, Selank does not impair cognitive function at anxiolytic doses — unlike benzodiazepines, it has been shown in clinical studies to maintain or slightly improve working memory and attention while reducing anxiety. This is its key research distinction.
Which Peptide for Which Research Goal?
BDNF / Neuroplasticity Research
Direct BDNF upregulation in hippocampus and cortex. The primary mechanistic target of Semax.
Anxiety / GAD Research
GABA-A modulation, serotonin transport inhibition. Phase 2/3 clinical data specifically for generalised anxiety disorder.
Stroke / Neuroprotection
Phase 3 stroke recovery data, VEGF upregulation, anti-inflammatory cytokine modulation. Registered in Russia for stroke.
Focus Without Stimulants
Mildly stimulatory nootropic profile via BDNF. Improves processing speed and focus without sympathomimetic effects.
Stress Resilience / PTSD
Multi-neurotransmitter anxiolytic without dependency risk. Reduces cortisol-driven stress response.
Combined Calm + Focus
Semax + Selank is the most studied cognitive stack — BDNF elevation plus GABAergic calm without overlap or antagonism.
Frequently Asked Questions
What is the difference between Semax and Selank?
Semax is an ACTH 4–10 analogue that primarily elevates BDNF (brain-derived neurotrophic factor), supports neuronal plasticity, and has Phase 3 clinical data for ischaemic stroke recovery. Its profile leans stimulatory — improving focus and cognitive processing. Selank is a stabilised analogue of tuftsin that modulates serotonin, dopamine, and GABA systems to produce anxiolytic effects without sedation or cognitive impairment. Its profile leans calming — reducing anxiety while maintaining or improving mental clarity.
Can you take Semax and Selank together?
Yes — Semax and Selank are commonly combined because their mechanisms are complementary rather than redundant. Semax provides the nootropic/BDNF component while Selank provides the anxiolytic/GABAergic component. The combination is sometimes described as producing focus and calm simultaneously — neuroplasticity support without anxiety.
Which is better for anxiety research — Semax or Selank?
Selank is the better compound for anxiety research. It acts on GABA-A receptors and modulates serotonin transport, producing measurable anxiolytic effects in clinical trials without the sedation, cognitive impairment, or dependency risk of benzodiazepines. Semax has secondary anxiolytic properties via BDNF elevation, but this is not its primary mechanism.
How is Semax administered?
Semax is primarily administered intranasally, which allows direct CNS delivery via the olfactory route and bypasses the blood-brain barrier. It can also be administered subcutaneously. The intranasal route is preferred in clinical research because it achieves rapid CNS effects at lower doses than systemic injection would require.
Research use only. All products sold by JA Performance are strictly for laboratory and in vitro research purposes. Not for human consumption, medical use, or veterinary use.